Related Experiment Video

Updated: Jan 3, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.1K

Apaziquone for Nonmuscle Invasive Bladder Cancer: Where Are We Now?

Tom J H Arends1, Johannes Alfred Witjes2

  • 1Department of Urology, Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 SZ Nijmegen, The Netherlands.

The Urologic Clinics of North America
|November 24, 2019
PubMed

Insights

Apaziquone shows potential for nonmuscle invasive bladder cancer treatment but failed to meet primary endpoints in phase 3 trials. Further research is needed, as drug development appears to have halted with no ongoing clinical trials.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Nonmuscle invasive bladder cancer (NMIBC) requires effective intravesical therapies.
  • Apaziquone is an investigational drug explored for NMIBC treatment.
  • Previous trials suggested potential benefits for apaziquone therapy.

Purpose of the Study:

  • To evaluate the efficacy and safety of apaziquone as an intravesical treatment for NMIBC.
  • To determine if apaziquone meets its primary endpoint in phase 3 clinical trials.

Main Methods:

  • The study involved patients with nonmuscle invasive bladder cancer undergoing intravesical treatment.
  • Phase 3 clinical trials were conducted to assess apaziquone's efficacy.
  • Primary endpoints were defined to measure treatment success.

Main Results:

  • Apaziquone demonstrated potential in clinical trials for NMIBC.
  • The singular phase 3 trials for apaziquone did not achieve their primary endpoint.
  • Currently, no new clinical trials for apaziquone are recruiting.

Conclusions:

  • Apaziquone's development for NMIBC appears to have ceased.
  • Further research is necessary to ascertain the definitive benefit of apaziquone.
  • The drug's clinical utility remains unproven due to trial outcomes.
Keywords:
ApaziquoneBladder cancerExperimentalNonmuscle invasiveTherapy

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.6K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
154
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
556